GlobeNewswire

2018 World Salt Symposium

Dela

Groundbreaking Evidence on Salt and Health to be presented

Naples, FL, USA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- The Tenth World Salt Symposium will be held June 19-21, 2018 in Park City, Utah, and will feature nearly 100 presentations from around the globe covering all topics related to salt. Starting in the 1960's, people from around the world have gathered to share information on the health benefits and uses of salt, salt mining practices, and solar salt production. The last such meeting was held in Beijing, China in 2009. The extended period between these conferences ensures a far-reaching and inclusive technical content. This is, without doubt, the most important international meeting focused on the subject of salt.

The Tenth World Salt Symposium is organized by the Salt Institute, in cooperation with several other salt organizations around the world. The World Salt Symposium focuses on the latest research and development in the international salt sector. It covers a wide spectrum of subjects, embracing the science, engineering, technology, economics and history of all forms of sodium chloride salt and their uses. As a broad international platform, the 2018 World Salt Symposium will enable researchers, producers and users of salt to become acquainted with the latest developments and technologies in this important industrial area.

Groundbreaking Evidence on Salt and Health

In the field of Salt and Health, we are pleased to announce that the following world-renowned experts, who have made unparalleled contributions to the field, have already committed to be keynote speakers at the upcoming symposium:

  • Dr. Michael Alderman, Albert Einstein College of Medicine, is editor of the American Journal of Hypertension, a fellow of the American College of Physicians, a member of the Association of American Physicians, and a past president of both the American Society of Hypertension and the International Society of Hypertension.
  • Dr. David McCarron, Research Associate in the Department of Nutrition, University of California-Davis and former Head of the Nephrology Division at Oregon Health & Science University. Dr. McCarron is a Fellow in the American College of Physicians and the AHA Council for High Blood Pressure Research. Dr. McCarron is the Chair of the Medical Nutrition Council of the American Society of Nutrition and a member of its Board of Directors.
  • Dr. Andrew Mente, Principal Investigator for the Epidemiology program at the Population Health Research Institute in Canada.
  • Dr. Suzanne Oparil, Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology, Section Chief of Vascular Biology and Hypertension and Director of the Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease in the Department of Medicine at the University of Alabama at Birmingham (UAB).
  • Dr. Jan Staessen, head of Hypertension and Cardiovascular Epidemiology in the Biomedical Sciences Group at KU Leuven University in Copenhagen.

In the field of Salt and Health we will also have special sessions with iodine experts. 

Salt Production Sessions

The Salt Production track of the symposium will cover a broad range of topics relating to all aspects of salt production, including mine safety, history of salt production, solar salt issues and possibilities for value added products in the salt marketplace. More than 60 papers will be presented in podium sessions and poster sessions, along with discussion sessions on safety topics. This will make the World Salt Symposium the global forum of choice for discussions on salt production.

Salt and the Environment

The Salt and the Environment track of the symposium will cover several topics that include a number of sessions and keynotes on the benefits of technological developments to the use of rock salt in winter maintenance and how these developments move forward the concept of safe and sustainable snowfighting. Additionally, several sessions will look at ways in which the salt production industry has worked to ensure that the various processes of producing salt also provide substantial environmental benefits.

"We are pleased to bring the World Salt Symposium back to the United States and to host this important event. The Salt Institute is also happy to announce that we have made our 55-year-old World Salt Symposia archive available on a new website that will serve as a permanent and public archive of all past and future papers presented at World Salt Symposia," said Lori Roman, President of the Salt Institute.

With over 300 flights arriving daily on nine airlines, Salt Lake City International Airport is just 45 minutes from Park City. Park City, Utah, is known for summer and winter beauty as well as its world renowned skiing, the Sundance Film Festival which draws celebrities from around the world, or the Utah Olympic Park. But summer time visitors can also experience the beautiful mountains, national parks, lakes, waterfalls and rivers which surround Park City. Registration, hotel and meeting agenda is available online at http://www.worldsaltsymposium.org/next-symposium/.

-30-

The Salt Institute is a North American based non-profit trade association dedicated to advancing the many benefits of salt, particularly to ensure winter roadway safety, quality water and healthy nutrition.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e3839002-a53b-4984-8126-92572bed3cb8

Jorge Amselle
Salt Institute
239-231-3305
jorge@saltinstitute.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Salt Institute via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum